• Paul McKenzie retires as CEO and Managing Director of CSL
• Gordon Naylor, former CSL senior executive, appointed as interim CEO and MD
• Naylor has 33 years of experience at CSL and played a key role in the company's global expansion

CSL Limited, a leading global biopharmaceutical company, has announced that Dr. Paul McKenzie will retire as Chief Executive Officer and Managing Director. The Board of Directors has appointed Gordon Naylor, a highly experienced former CSL senior executive and non-executive director, as the interim CEO and MD, effective February 11, 2026. Dr. Brian McNamee AO, the CSL Chair, expressed the Board's gratitude to Dr. McKenzie for his commitment and contributions to the company over the past seven years, including his three years as CEO. During his tenure, Dr. McKenzie guided CSL's global operations through the challenges of COVID-19, stabilized manufacturing and supply chains, and increased plasma collection volumes beyond pre-pandemic levels. He also led the introduction of new therapies such as HEMGENIX®, the world's first gene therapy for haemophilia B, and ANDEMBRY® for hereditary angioedema, as well as the transformation of CSL's end-to-end operations.The Board is pleased to appoint Gordon Naylor as the interim CEO and MD. Naylor has a proven track record and deep knowledge of CSL, having played a pivotal role in the company's rise to global leadership in plasma therapies and vaccines during his 33-year tenure. He has held various senior leadership roles, including Chief Financial Officer and President of Seqirus, and was instrumental in the acquisitions that established CSL's global position in plasma, Behring, and Seqirus. Naylor will work closely with the Board and the leadership team to execute CSL's strategic transformation and deliver for patients, public health, and shareholders.Dr. McKenzie will step down as CEO and MD on February 10, 2026, and his existing awards will be treated in accordance with their original terms upon his retirement.